Cambridge Investment Research Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $26 Billion
- Q1 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 2,384 shares of MDGL stock, worth $693,124. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,384
Previous 6,157
61.28%
Holding current value
$693,124
Previous $1.43 Million
55.3%
% of portfolio
0.0%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding MDGL
# of Institutions
314Shares Held
20MCall Options Held
824KPut Options Held
1.04M-
Janus Henderson Group PLC London, X02.6MShares$756 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$573 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$565 Million6.26% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.78MShares$516 Million34.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$485 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.97B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...